이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Alzamend Neuro 관리

관리 기준 확인 4/4

Alzamend Neuro's CEO는 Stephan Jackman, Nov2018 에 임명되었습니다 의 임기는 5.58 년입니다. 총 연간 보상은 $ 2.22M, 13.5% 로 구성됩니다. 13.5% 급여 및 86.5% 보너스(회사 주식 및 옵션 포함). 는 $ 1.21K 가치에 해당하는 회사 주식의 0.041% 직접 소유합니다. 1.21K. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 3 년입니다.

주요 정보

Stephan Jackman

최고 경영자

US$443.6k

총 보상

CEO 급여 비율	78.9%
CEO 임기	5.8yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	5.3yrs
이사회 평균 재임 기간	3.2yrs

최근 관리 업데이트

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

CEO 보상 분석

Stephan Jackman 의 보수는 Alzamend Neuro 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 30 2024	US$444k	US$350k	-US$10m
Jan 31 2024	n/a	n/a	-US$12m
Oct 31 2023	n/a	n/a	-US$15m
Jul 31 2023	n/a	n/a	-US$15m
Apr 30 2023	US$2m	US$300k	-US$15m
Jan 31 2023	n/a	n/a	-US$15m
Oct 31 2022	n/a	n/a	-US$13m
Jul 31 2022	n/a	n/a	-US$13m
Apr 30 2022	US$473k	US$303k	-US$12m
Jan 31 2022	n/a	n/a	-US$10m
Oct 31 2021	n/a	n/a	-US$8m
Jul 31 2021	n/a	n/a	-US$6m
Apr 30 2021	US$225k	US$225k	-US$5m
Jan 31 2021	n/a	n/a	-US$5m
Oct 31 2020	n/a	n/a	-US$5m
Jul 31 2020	n/a	n/a	-US$5m
Apr 30 2020	US$2m	US$188k	-US$4m
Jan 31 2020	n/a	n/a	-US$4m
Oct 31 2019	n/a	n/a	-US$4m
Jul 31 2019	n/a	n/a	-US$4m
Apr 30 2019	US$3m	US$50k	-US$5m

보상 대 시장: Stephan 의 총 보상 ($USD 443.62K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 670.33K ).

보상과 수익: Stephan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Stephan Jackman (48 yo)

5.8yrs

테뉴어

US$443,617

보상

Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and has been its Director since September 2020. Mr. Jackman has experience in administration, business a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephan Jackman	CEO & Director	5.8yrs	US$443.62k	0.036% $ 646.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	1.98% $ 35.6k
David Katzoff	Chief Financial Officer	2yrs	US$150.00k	0.064% $ 1.2k
Henry C. Nisser	Executive VP	5.3yrs	US$50.00k	0% $ 0
Kenneth Cragun	Senior Vice President of Finance	3.2yrs	데이터 없음	0% $ 0

5.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: ALZN 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stephan Jackman	CEO & Director	3.9yrs	US$443.62k	0.036% $ 646.9
Milton Ault	Founder & Vice Chairman	less than a year	US$8.33k	1.98% $ 35.6k
Henry C. Nisser	Executive VP	3.9yrs	US$50.00k	0% $ 0
William Horne	Chairman of the Board	8.2yrs	US$50.00k	0.79% $ 14.2k
Mark Gustafson	Independent Director	3.2yrs	US$25.00k	0.048% $ 854.0
Lynne McGrath	Independent Director	3.2yrs	US$25.00k	0.059% $ 1.1k
Thomas Wisniewski	Member of Scientific Advisory Board	5.1yrs	데이터 없음	데이터 없음
Eric McDade	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Oram	Independent Director	3.2yrs	US$25.00k	0.079% $ 1.4k
Andrew Woo	Independent Director	3.2yrs	US$25.00k	0.079% $ 1.4k
Terri Hunter	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: ALZN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Alzamend Neuro 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

High number of new and inexperienced directors

Alzamend Neuro, Inc. Announces CFO Changes

No independent directors

Recent updates

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro closes $14.4M IPO

Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령